Evidence map›Paper›PMID 40838047›Full record

ReviewFrontiers in drug delivery2023

Transnasal-brain delivery of nanomedicines for neurodegenerative diseases.

Xu Zhang, Maohua Wang, Zhixian Liu, Ying Wang, Li Chen, Jiaqi Guo, Wentao Zhang, Yao Zhang, Chenjie Yu, Tongwu Bie and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xu ZhangDepartment of Otolaryngology, Head and Neck Surgery, Dalian Medical University, Dalian, China.
Maohua WangDepartment of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Foshan, Hearing and Balance Medical Engineering Technology Center of Guangdong, Foshan, China.
Zhixian LiuDepartment of Otolaryngology, Head and Neck Surgery, Shenzhen Hengsheng Hospital, Shenzhen, China.
Ying WangDepartment of Otolaryngology, Head and Neck Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China.
Li ChenDepartment of Otolaryngology, Head and Neck Surgery, Dalian Medical University, Dalian, China.
Jiaqi GuoDepartment of Otolaryngology, Head and Neck Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China.
Wentao ZhangDepartment of Otolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yao ZhangDepartment of Otolaryngology, Head and Neck Surgery, Dalian Medical University, Dalian, China.
Chenjie YuJiangsu Provincial Key Medical Discipline (Laboratory), Department of Otolaryngology, Head and Neck Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Tongwu BieDepartment of Otolaryngology, Head and Neck Surgery, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Youjun YuDepartment of Otolaryngology, Head and Neck Surgery, The First People's Hospital of Foshan, Hearing and Balance Medical Engineering Technology Center of Guangdong, Foshan, China.
Bing GuanDepartment of Otolaryngology, Head and Neck Surgery, Clinical Medical College, Yangzhou University, Yangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases (NDs) have become a serious global health problem as the population ages. Traditionally, treatment strategies for NDs have included oral and intravenous administration; however, the blood-brain barrier (BBB) can prevent drugs from reaching the brain, rendering the treatment incomplete and the effect unsatisfactory. Additionally, the prolonged or excessive use of drugs that can cross the BBB can damage liver and kidney function. Recent studies have shown that nose-to-brain drug delivery can noninvasively bypass the BBB, allowing drugs to enter the brain through the olfactory or trigeminal nerve pathways; additionally, nanoparticle carriers can enhance drug delivery. This review introduces drug carrier nanoparticles for nose-to-brain delivery systems, compares the advantages and disadvantages of different nanoparticles, and discusses the factors influencing nose-to-brain nanomedicine delivery and enhancement strategies. We also summarize nose-to-brain delivery and nanomedicines for treating NDs, the current challenges of this approach, and the future promise of nanomedicine-based ND treatment.

Indexed as

delivery methodsexosomesinfluencing factorsnanomedicinesneurodegenerative diseasesnose-to-brain deliverystrategies

Identifiers

PMID40838047
PMCPMC12363324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.